abbvie-gp2020
Phase 1
AbbVieabbvie-gp2020 is one of 38 therapeutic programs targeting Inflammatory Bowel Disease. It is currently in Phase 1.
1
Indications
0
Total Trials
0
Active Trials
37
Competitors
Pipeline
Status by Indication[1]
Indication
Competition
Competitive Landscape
151 competitors in Inflammatory Bowel Disease
#DrugCompanyPhaseTrials
1Remicade
OOrganon and Co
Phase 3
Stelara
Johnson & JohnsonPhase 3
Thalomid
Bristol-Myers SquibbPhase 3
Farxiga
AstraZenecaPhase 3
Humira
CCelltrion
Phase 3
Omvoh
Eli LillyPhase 3
Valcyte
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Deltavit
HHyundai Pharmaceutical Co., LTD.
Phase 3
Jyseleca
GileadPhase 2
Iron Sulphate
PPierre Fabre Pharma GmbH
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for abbvie-gp2020. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1
- Company